RT Journal Article
SR Electronic
T1 A next generation CRISPR diagnostic tool to survey drug resistance in Human African Trypanosomiasis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.15.24313552
DO 10.1101/2024.09.15.24313552
A1 Antón, Elena Pérez
A1 Dujeancourt-Henry, Annick
A1 Rotureau, Brice
A1 Glover, Lucy
YR 2024
UL http://medrxiv.org/content/early/2024/09/17/2024.09.15.24313552.abstract
AB The WHO aims to eliminate the gambiense form of human African trypanosomiasis (HAT) by 2030. With the decline of reported cases, maintaining efficient epidemiological surveillance is essential, including the emergence of drug-resistant strains. We have developed new highly specific diagnostic tools using Specific High-Sensitivity Reporter Enzymatic UnLOCKing (SHERLOCK) technology for monitoring the presence of drug-resistant genotypes that (1) are already circulating, such as the AQP2/3(814) chimera providing resistance to pentamidine and melarsoprol, or (2) could emerge, such as TbCPSF3 (N232H), associated to acoziborole resistance in lab conditions. The melarsoprol - pentamidineAQP2/3(814) SHERLOCK assay detected RNA from both cultured parasites and field isolated strains from gHAT patients in relapse following treatment. The acoziborole CPSF3(SNV)SHERLOCK assay discriminated between wild-type CPSF3 RNA and CPSF3 with a single A-C mutation that confers resistance to acoziborole in vitro.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project has received funding from the Agence Nationale pour la Recherche (ANR-PRC 2021 SherPa). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used openly T. b. gambiense isolates from human infections provided by: 1)Dr. Nick Van Reet (Institute of Tropical Medicine, Antwerp) - The parasite strains isolated and use for research purposes was approved by the Ethical Committee of the Institute of Tropical Medicine (04441472) and of the Ministry of Health of DRC [25]. The strains are anonymized by using international codes and alias names.)https://doi.org/10.1371/journal.pntd.0003212) 2)Pr. Pascal Maeser (Swiss Tropical and Public Health Institute, Switzerland) - Parasite strains isolated and propagated in rodents were used for research purposes only. The WHO and the Ministry of Health of Sudan People's Liberation Army (SPLA) approved the study protocol (https://doi.org/10.1016/j.trstmh.2006.11.008)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors